- Home
- MKZR vs GNPX Comparison
MKZR vs GNPX Comparison
Compare MKZR & GNPX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MKZR
- GNPX
- Stock Information
- Founded
- MKZR 2012
- GNPX 2009
- Country
- MKZR United States
- GNPX United States
- Employees
- MKZR N/A
- GNPX N/A
- Industry
- MKZR
- GNPX Biotechnology: Pharmaceutical Preparations
- Sector
- MKZR
- GNPX Health Care
- Exchange
- MKZR Nasdaq
- GNPX Nasdaq
- Market Cap
- MKZR 10.3M
- GNPX 10.8M
- IPO Year
- MKZR N/A
- GNPX 2018
- Fundamental
- Price
- MKZR $4.20
- GNPX $2.97
- Analyst Decision
- MKZR
- GNPX
- Analyst Count
- MKZR 0
- GNPX 0
- Target Price
- MKZR N/A
- GNPX N/A
- AVG Volume (30 Days)
- MKZR 32.1K
- GNPX 299.4K
- Earning Date
- MKZR 11-14-2025
- GNPX 11-14-2025
- Dividend Yield
- MKZR 24.69%
- GNPX N/A
- EPS Growth
- MKZR N/A
- GNPX N/A
- EPS
- MKZR N/A
- GNPX N/A
- Revenue
- MKZR $20,994,778.00
- GNPX N/A
- Revenue This Year
- MKZR N/A
- GNPX N/A
- Revenue Next Year
- MKZR N/A
- GNPX N/A
- P/E Ratio
- MKZR N/A
- GNPX N/A
- Revenue Growth
- MKZR 3.63
- GNPX N/A
- 52 Week Low
- MKZR $3.86
- GNPX $2.77
- 52 Week High
- MKZR $50.00
- GNPX $63.00
- Technical
- Relative Strength Index (RSI)
- MKZR 38.42
- GNPX 42.93
- Support Level
- MKZR $3.92
- GNPX $2.77
- Resistance Level
- MKZR $4.86
- GNPX $5.00
- Average True Range (ATR)
- MKZR 0.41
- GNPX 0.48
- MACD
- MKZR -0.05
- GNPX -0.27
- Stochastic Oscillator
- MKZR 20.88
- GNPX 8.07
About MKZR MacKenzie Realty Capital Inc.
Mackenzie Realty Capital Inc is a company which is a Real estate investment trust (REIT). The company has one reportable segment, income-producing real estate properties which consists of activities related to investing in real estate.
About GNPX Genprex Inc.
Genprex Inc is a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes. Its technologies are designed to administer disease-fighting genes to provide new therapies for large patient populations with cancer and diabetes who currently have limited treatment options. Genprex's oncology program utilizes its systemic, non-viral Oncoprex Delivery System which encapsulates the gene-expressing plasmids using lipid-based nanoparticles in a lipoplex form. The company's product candidate, Reqorsa Immunogene Therapy (quaratusugene ozeplasmid), is being evaluated in three clinical trials as a treatment for NSCLC and SCLC.